Depomed is committed to becoming a leader in the clinical development and commercialization of therapies for pain management and other central nervous system (CNS) conditions. The company’s two current products, Gralise and Zipsor, have established Depomed’s expertise in building effective marketing strategies and solutions-oriented sales teams. The company intends to leverage this growing domain expertise with additional CNS products. DM-1992 (for Parkinson’s Disease) is currently poised to begin phase 3 clinical trials, and the company is actively assessing other well-characterized compounds for in-licensing and development.
For more information, please visit www.gralise.com.
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Zipsor, like all nonsteroidal anti-inflammatory drugs (NSAIDs), may cause increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (Warnings and Precautions 5.1)
Zipsor is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. (Contraindications 4)
NSAIDs, including Zipsor, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach and intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (Warnings and Precautions 5.2)
See full prescribing information for complete boxed warning.
See full Prescribing Information including Boxed WARNING regarding cardiovascular and gastrointestinal risks
For more information, please visit www.zipsor.com.
If you have any questions regarding our marketed products, please call 1.866.458.6389.